Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Avenue Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ATXI
Nasdaq
2834
https://avenuetx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Avenue Therapeutics Inc
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
- Mar 25th, 2024 12:30 pm
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
- Mar 18th, 2024 8:05 pm
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
- Mar 15th, 2024 12:15 pm
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
- Mar 11th, 2024 12:00 pm
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
- Feb 22nd, 2024 1:30 pm
Sidoti Events, LLC's Virtual January Micro-Cap Conference
- Jan 16th, 2024 1:40 pm
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
- Jan 11th, 2024 1:00 pm
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
- Jan 5th, 2024 2:15 pm
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
- Jan 4th, 2024 1:30 pm
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
- Jan 2nd, 2024 1:30 pm
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
- Dec 1st, 2023 1:30 pm
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
- Nov 13th, 2023 9:05 pm
Avenue Therapeutics' US$4.5m Market Cap Fall Books Insider Losses
- Nov 6th, 2023 1:38 pm
Avenue Therapeutics Announces Closing of $5.0 Million Public Offering
- Nov 2nd, 2023 7:00 pm
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
- Oct 31st, 2023 1:15 pm
Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
- Sep 5th, 2023 12:30 pm
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
- Aug 14th, 2023 8:01 pm
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
- Aug 10th, 2023 8:15 pm
Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study
- Aug 1st, 2023 12:30 pm
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
- Jul 27th, 2023 12:30 pm
Scroll